Browse the evidence

Dietary interventions targeting gut microbiota composition (e.g., prebiotics, probiotics, or specific fiber types) can improve glucose homeostasis and insulin sensitivity in obese individuals, particularly by modulating the Firmicutes/Bacteroidetes ratio and reducing pro-inflammatory bacterial species.

Focus on dietary fibers and fermented foods to support a healthy gut microbiome. This may help improve insulin sensitivity and reduce inflammation, which are key drivers of obesity and metabolic syndrome.

High consumption of ultra-processed foods (UPFs) is associated with specific alterations in gut microbiota composition, including decreased Lachnospira and Ruminococcus species and increased Prevotella species, though effects on overall microbial diversity (alpha/beta) are inconsistent across studies.

If you consume a high amount of ultra-processed foods, you may see a shift in your gut bacteria, specifically a decrease in beneficial fiber-fermenting types like Lachnospira and an increase in Prevotella. While overall diversity might not change significantly in all cases, these specific shifts are linked to higher UPF intake. To support a healthier microbiome, consider reducing UPF intake and increasing fiber-rich whole foods.

High consumption of ultra-processed foods is associated with negative health outcomes including increased depression/anxiety, higher BMI/weight, and decreased HDL cholesterol, particularly in men consuming >5 servings/day.

Eating more than 5 servings of ultra-processed foods daily is linked to higher body weight, worse cholesterol (lower HDL in men), and higher rates of depression and anxiety in women. Reducing UPF intake below this threshold may help improve these health markers.

GLP-1 agonists (specifically liraglutide and exenatide) induce significant weight loss in patients with antipsychotic-induced weight gain (AIWG) without worsening psychiatric symptoms.

For patients gaining weight from antipsychotics, GLP-1 agonists like liraglutide or exenatide are effective tools for weight loss. Liraglutide shows stronger results (-4.7 kg) than exenatide (-2.5 kg). These drugs do not worsen mental health symptoms, making them safe adjuncts to antipsychotic therapy. Side effects like nausea are common but usually manageable.

Individual metabolic and hormonal adaptations, including somatotype-specific responses and adaptive thermogenesis, drive significant variability in weight management outcomes, rendering the 'calories in, calories out' model insufficient for personalized strategies.

Stop assuming that a calorie is just a calorie for everyone. Your body's hormonal and metabolic response to food and restriction is unique. To succeed, you need to move beyond simple calorie counting and consider personalized strategies like precision nutrition, which may involve analyzing your metabolic profile, hormonal status, and even genetic factors to tailor your diet and exercise.

Somatotypes (ectomorph, mesomorph, endomorph) correspond to distinct metabolic and hormonal profiles that influence individual responses to diet and exercise, suggesting tailored interventions are more effective.

Understand your body type as a starting point for tailoring your approach. Ectomorphs may need high-protein and resistance training to preserve muscle. Mesomorphs may respond well to balanced macronutrients and strength training. Endomorphs may benefit from low-GI diets and stress management to modulate insulin and cortisol. Use this framework to personalize your strategy.

Semaglutide treatment resolves prediabetes and normalizes HbA1c levels in post-bariatric patients, even in those who did not achieve full diabetes remission post-surgery.

If you had bariatric surgery and still have prediabetes, semaglutide can help normalize your blood sugar levels. In this study, all patients with prediabetes who took semaglutide for a year achieved normal glucose levels. This highlights the importance of ongoing metabolic management after surgery.

GLP-1 receptor agonists (GLP-1 RAs) improve sperm parameters (concentration, motility, morphology) and testosterone levels in obese men with metabolic hypogonadism, primarily through weight loss and direct testicular effects.

If you are obese and struggling with fertility, GLP-1 medications like semaglutide or liraglutide may help improve your sperm count and testosterone levels, not just by helping you lose weight, but potentially by directly supporting testicular function. The key is working with a doctor to start with a low dose and slowly increase it to minimize stomach issues. While these drugs are expensive, the potential for improved fertility and sustained weight loss might justify the cost compared to other treatments.

GLP-1-based therapies improve medication adherence in patients with resistant hypertension by reducing the burden of multiple daily antihypertensive drugs.

If you struggle to take multiple blood pressure pills every day, a GLP-1 medication might help. It can lower your blood pressure and help you lose weight, potentially allowing your doctor to reduce the number of other blood pressure medications you need. This simplification often makes it easier to stick with your treatment plan.

Omega-3 fatty acid supplementation increases muscle volume, strength, and muscle protein synthesis in elderly adults, potentially by activating the mTOR pathway and reducing inflammation.

Consider adding Omega-3 fatty acids to your diet, either through fatty fish or supplements, as they may help increase muscle strength and volume in older adults, even if you are not exercising. However, more research is needed specifically for Indian populations.

Leucine supplementation (isolated or enriched) improves lean body mass, muscle strength, and physical functioning in sarcopenic or elderly populations.

Ensure your protein sources are rich in leucine, or consider leucine-enriched protein supplements. Studies show this can improve muscle mass and walking ability in older adults, especially those with sarcopenia. However, more research is needed for Indian populations.

Semaglutide administration (up to 1 mg weekly) produces significant weight and BMI reduction in obese patients with kidney failure undergoing dialysis, with a side effect profile comparable to non-dialysis populations.

If you are on dialysis and obese, semaglutide injections (starting at 0.25mg and increasing to 1mg weekly) can help you lose significant weight (average 4.6kg in 12 weeks) with manageable side effects like mild nausea. This weight loss may allow you to qualify for kidney transplantation, which offers better survival and quality of life than remaining on dialysis. Consult your nephrologist about this off-label use.

Switching from continuous full-dose GLP-1/IM therapy to a lower-cost, less effective alternative weight-maintenance program after reaching a weight-loss plateau generates substantial lifetime healthcare savings with only minimal reductions in quality-adjusted life years (QALYs).

If you have successfully lost weight using GLP-1 medications (like Wegovy or Ozempic) and your weight has stabilized, discuss with your doctor whether switching to a lower-cost maintenance strategy (such as a lower dose, a different medication, or a focus on lifestyle/nutrition support) is appropriate for you. This approach may save you significant money and reduce side effects while maintaining a substantial portion of your health benefits, with the option to return to full-dose therapy if you regain weight.

Myostatin acts as a negative regulator of muscle hypertrophy and cardiac pathological hypertrophy, and its inhibition or reduction through exercise can promote muscle growth and protect against certain cardiac dysfunctions.

Consistent exercise naturally lowers myostatin, a protein that limits muscle growth. This is one reason why regular resistance training is effective for building muscle.

Tirzepatide, a dual GLP-1/GIP receptor agonist, promotes significant weight loss and improves metabolic parameters in obese patients with PCOS, potentially offering superior tolerability compared to GLP-1R agonists alone due to its imbalanced receptor affinity.

For obese individuals with PCOS, tirzepatide is a once-weekly injection that helps with weight loss and blood sugar control. It works by mimicking hormones that regulate appetite and insulin. While it can cause stomach upset, the dual-action design might make it easier to tolerate than older drugs. It is not a substitute for lifestyle changes but can be a powerful tool when combined with diet and exercise.

Sustained increases in accelerometer-measured moderate-to-vigorous physical activity (MVPA) over 4 years are associated with a reduced risk of cardiovascular disease (CVD) outcomes in adults with type 2 diabetes, whereas short-term (1-year) changes are not.

To lower your cardiovascular disease risk, you need to maintain a consistent level of moderate-to-vigorous physical activity (like brisk walking) for several years, not just a few months. Simply exercising for a year is not enough to see a reduction in risk. Focus on long-term adherence to an active lifestyle rather than short-term bursts.

Daily consumption of 30g of dark chocolate (83% cocoa) for 12 weeks significantly reduces body weight, BMI, and serum AST levels in patients with Non-Alcoholic Fatty Liver Disease (NAFLD).

If you have NAFLD, consuming 30 grams of dark chocolate (at least 83% cocoa) daily for 12 weeks may help reduce your body weight, BMI, and liver enzyme levels (AST). This suggests that specific high-cocoa dark chocolate can be part of a liver-healthy diet, contrary to the general belief that all chocolate causes weight gain.

Pre-contest preparation in physique athletes involves significant caloric restriction and high-volume training, leading to marked alterations in body composition, hormonal profiles, and psychometric outcomes, with sex-specific divergent responses in lean mass and hormone regulation.

If you are preparing for a physique competition, expect significant changes. You will likely lose 8-9% body fat over 3-8 months. Men may lose lean mass despite high protein intake, while women may maintain or slightly gain it. Hormones like testosterone will drop in men, and cortisol will rise in both sexes. Sleep quality and mood may suffer. This is a controlled stressor; manage it with consistent resistance training and gradual caloric deficits.

Highly effective anti-obesity medications (heAOMs) achieving 15% or more weight reduction can cause 'excessive weight reduction' leading to psychosocial challenges, nutrient deficiencies, and lean body mass loss, requiring proactive management including body composition analysis and behavioral support.

If you are taking a powerful weight loss medication and losing weight rapidly (15% or more), you need to monitor more than just your weight. Ask your doctor for a body composition analysis to ensure you aren't losing too much muscle or essential fat. Prioritize protein intake and resistance training to protect your muscle. Be prepared for changes in your social relationships and mental health, and seek support if you feel isolated or if friends/family react negatively to your changes.

GLP-1 receptor agonists (GLP-1 RAs) are not standalone cures for obesity but function as 'training wheels' that facilitate the adoption of sustainable lifestyle changes, requiring active patient engagement in diet and exercise to prevent weight regain.

Do not view GLP-1 medication as a substitute for healthy habits. Use the appetite suppression it provides to practice making better food choices and increasing physical activity. The goal is to use the medication to learn how to maintain a healthy weight independently, so you can eventually taper off while keeping the lifestyle changes.

Proactive management of gastrointestinal side effects (nausea, constipation, diarrhea) through dietary adjustments (hydration, fiber, smaller meals) is critical for maintaining patient adherence to GLP-1 therapy.

If you experience nausea, constipation, or diarrhea, do not just push through it. Increase water intake, try ginger or peppermint tea, and eat smaller, more frequent meals. If constipation persists, increase dietary fiber and physical activity. These adjustments can help you stay on the medication without suffering.

Male gym-goers are significantly more likely to consume protein supplements than females, primarily to gain muscle mass, with consumption often occurring immediately post-exercise.

If you are a male gym-goer in Saudi Arabia, you are statistically likely to use protein powder (1-2 scoops) right after your workout to build muscle. Be aware that nearly 70% of users experience gastrointestinal side effects like nausea or diarrhea. If you are female, you are less likely to use them, often preferring bars or snacks. Regardless of gender, verify your protein needs with a professional, as coaches are the main source of advice but may not be nutrition experts.

Early Time-Restricted Eating (eTRE) offers specific cardiometabolic benefits (glucose tolerance, insulin sensitivity) independent of weight loss, though practical adherence is low.

If you want metabolic health benefits, try finishing your last meal by 3 PM. However, be aware this is socially difficult and may not be sustainable long-term. If you can't do it, standard timing with good food quality is better than quitting.

GLP-1RAs and GIP/GLP-1RAs (liraglutide, semaglutide, tirzepatide) cause significant loss of fat-free (muscle) mass in older adults with sarcopenic obesity, posing a risk that may outweigh benefits if not managed.

If you are an older adult with sarcopenic obesity considering GLP-1 medications, expect to lose some muscle along with fat. To protect your strength, you must combine the medication with regular resistance exercise and eat enough protein (1.0-1.2g per kg of body weight). Work with your doctor to start slowly and monitor your function.